Teva Pharmaceutical Industries Sees Unusually High Options Volume (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) saw unusually large options trading on Tuesday. Traders bought 27,298 call options on the company. This is an increase of 82% compared to the average volume of 14,998 call options.

Teva Pharmaceutical Industries Stock Up 6.2%

Teva Pharmaceutical Industries stock opened at $30.12 on Wednesday. The company has a market capitalization of $34.63 billion, a PE ratio of 25.10, a PEG ratio of 9.52 and a beta of 0.72. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $37.35. The firm’s fifty day moving average is $32.24 and its 200 day moving average is $27.61. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period last year, the company posted $0.71 earnings per share. The business’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 14,150 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $448,130.50. Following the completion of the transaction, the insider owned 6,774 shares in the company, valued at approximately $214,532.58. This trade represents a 67.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric A. Hughes sold 9,533 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $301,910.11. Following the completion of the transaction, the insider owned 107,711 shares in the company, valued at $3,411,207.37. This trade represents a 8.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 920,901 shares of company stock valued at $30,056,789 over the last three months. Insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in TEVA. Aster Capital Management DIFC Ltd purchased a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $25,000. Allworth Financial LP raised its position in Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after buying an additional 329 shares during the last quarter. Grove Bank & Trust lifted its stake in Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Teva Pharmaceutical Industries by 567.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock worth $42,000 after acquiring an additional 1,134 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TEVA. Piper Sandler reissued an “overweight” rating and set a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Jefferies Financial Group lifted their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Bank of America boosted their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Barclays upped their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.